Mundipharma Expands Specialised Cancer Treatment Portfolio with the Acquisition of Spectrum’s Japan Affiliate and Multi-market ZEVALIN® Acquisition

November 18, 2015 - 6 minutes read
  • Acquisition from Spectrum Pharmaceuticals leverages upon Mundipharma’s existing regulatory and marketing investments.
  • Under the License and Asset Purchase Agreement, Mundipharma will have all rights related to research, development, marketing, sales, and intellectual property rights and access to existing inventory of ZEVALIN® from Spectrum Pharmaceuticals in all countries except US, Canada, Europe, Russia/CIS, India and China.

Singapore, 18 November, 2015: Mundipharma International Corporation Limited has announced that it has entered into a License and Asset Purchase Agreement to acquire the rights to sell and distribute ZEVALIN® (Ibritumomab tiuxetan) injection for intravenous use from Spectrum Pharmaceuticals. ZEVALIN® is currently approved in more than 40 countries for the treatment of follicular B-cell Non-

Hodgkin’s lymphoma, including countries in Europe, Latin America and Asia. Under the Agreement, Mundipharma will have rights related to marketing and sales and access to existing inventory of ZEVALIN® from Spectrum across Asia Pacific including Japan and additionally Latin America, Middle East, Africa and Israel. Mundipharma will also acquire Spectrum Pharmaceuticals GK, Spectrum’s Japanese affiliate, which offers Japanese patients improved access to ZEVALIN® treatments.

ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that has three parts: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN® (In Japan, the approved administration of ZEVALIN® is two treatments of rituximab, one treatment of Indium-111 (In-111) and one treatment of Yttrium-90 (Y-90)). Rituximab is administered prior to ZEVALIN® with the goal of clearing the majority of normal B-cells so that ZEVALIN® is more focused on tumor cells. The ZEVALIN® therapeutic regimen is used to treat patients with recurring, low-grade or follicular B-cell NHL, after other anti-cancer drugs are no longer working and newly diagnosed follicular NHL following a response to initial anticancer therapy. A June 2013 study concluded that (90)Y-ibritumomab consolidation after achieving PR or CR/CRu to induction confers 3-year benefit in median progression-free survival (PFS) with durable 19% PFS advantage at 8 years1.

1 Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.J Clin Oncol. 2013; 31(16):1977-83

 

Raman Singh, President of Mundipharma Asia Pacific, Latin America, Middle East and Africa, said, “Mundipharma is passionately committed to bringing innovative, effective and safe treatments to patients everywhere. There is a great unmet need in the treatment of follicular lymphoma and it is our responsibility as a company to harness innovation to provide patients with easier access to therapeutic strategies, such as ZEVALIN®, to improve the quality of their lives. ZEVALIN® presents healthcare professionals with access to a treatment option which can markedly improve the quality of their patients’ lives as it has one of the best proven progression free survival results for these difficult to treat patients.”

ZEVALIN® (ibritumomab tiuxetan) Injection for intraveneous use
ZEVALIN® is a combination of two prescription medications. It is given with two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN®. Rituximab is administered prior to ZEVALIN® with the goal of clearing the majority of normal B-cells so that ZEVALIN® is more focused on tumor cells.

About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as severe pain, oncology, respiratory disease rheumatoid arthritis, antiseptics and laxatives.

For more information please visit:  www.mundipharma.com.sg.

About Spectrum
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum markets three oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum’s strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at  www.sppirx.com.

For further information please contact:
Stephenie Vasko
Communications Director – Asia, Latin America, Middle East and Africa PH +65-6303-9732
stephenie.vasko@mundipharma.com.sg
www.mundipharma.com.sg

Tags: